Pfizer shares more promising results from COVID-19 study

By Jenni Spinner contact

- Last updated on GMT

(Margarita Cheblokova/iStock via Getty Images Plus)
(Margarita Cheblokova/iStock via Getty Images Plus)

Related tags: COVID-19, Coronavirus, Pfizer, Oral drug delivery, Phase II, Phase 3

According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.

Pfizer has released final data from its EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) Phase II/III study. The findings reportedly confirm earlier results of interim analysis showing its Paxlovid treatment (nirmatrelvir and ritonavir tablets) reduced the risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo; additionally, it showed no deaths compared to placebo in non-hospitalized, high-risk adults with COVID-19.

OSP_PfizerCovid_AB
Albert Bourla, CEO and chairman, Pfizer

This news provides further corroboration that our oral antiviral candidate, if authorized or approved, could have a meaningful impact on the lives of many, as the data further support the efficacy of Paxlovid in reducing hospitalization and death and show a substantial decrease in viral load​,” said Albert Bourla, CEO and chairman of Pfizer. “This underscores the treatment candidate’s potential to save the lives of patients around the world.”

“Emerging variants of concern, like omicron, have exacerbated the need for accessible treatment options for those who contract the virus,” Bourla added. “We are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic.”

Pfizer also reported 0.7% of patients who received Paxlovid were hospitalized through Day 28 following randomization (5/697 hospitalized with no deaths), compared to 6.5% of patients who received placebo and were hospitalized or died (44/682 hospitalized with nine subsequent deaths). The statistical significance of these results was high (p<0.0001).

In a secondary endpoint, Paxlovid reportedly reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset; 0.8% of patients who received PAXLOVID were hospitalized or died through Day 28 following randomization (8/1039 hospitalized with no deaths), compared to 6.3% of patients who received placebo (66/1046 hospitalized with 12 subsequent deaths), with high statistical significance (p<0.0001).

Additionally, relative risk reduction in patients 65 years of age or older (one of the populations at highest risk for hospitalization or death) was 94%, and 1.1% of patients who received the treatment were hospitalized through Day 28 (1/94 hospitalized with no deaths), compared to 16.3% of patients who received placebo (16/98 hospitalized with 6 deaths), with high statistical significance (p<0.0001).

In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid. That figure is compared to 12 (1.2%) deaths in patients who received a placebo.

In a secondary endpoint in the trial, SARS-CoV-2 viral load at baseline and Day 5 were evaluated for 499 patients. After accounting for baseline viral load, geographic region, and serology status, Paxlovid reportedly reduced viral load by approximately tenfold, relative to placebo, indicating robust activity against SARS-CoV-2 and representing the strongest viral load reduction reported to date for an oral COVID-19 agent.

 Treatment-emergent adverse events were comparable between the treatment (23%) and placebo (24%), most of which were mild in intensity. Fewer serious adverse events (1.6% compared to 6.6%) and discontinuation of study drug due to adverse events (2.1% vs. 4.2%) were observed in patients dosed with Paxlovid, compared to placebo, respectively.

Full study data are expected to be released later this month and submitted to a peer-reviewed publication.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars